Clinical trials: MRD
Ph+ ALL, Bone Marrow Transplant
A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive
Hematopoietic stem cell transplantation (HSCT) is the effective and even the only cure treatment option for ph+ acute lymphocyte leukemia (ph+ALL).
- Conditions
- Ph+ ALL, Bone Marrow Transplant, Minimal Residual Disease
- Trial name
- NCT05603156
- Testing
- the usage of Olverembatinib combined with Inotuzumab Ozogamicin
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD
The purpose : Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.
- Trial name
- TELO - DMRD (NCT05530096)
- Testing
- Standard of care
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Non-small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to see whether receiving local ablative therapy (LAT) when minimal residual disease/MRD levels are rising can reduce MRD levels and control metastatic non-small cell lung cancer/NSCLC longer compared…
- Conditions
- Non-small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Nsclc, NSCLC Stage IV
- Trial name
- NCT05429320
- Testing
- Local ablative therapy, Blood collection to assess for ctDNA
- Where
- 9 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer, Nonsmall Cell
ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
This study aims to incorporate circulating tumor DNA (ctDNA)-minimal residual disease (MRD) to personalize the administration of consolidation toripalimab therapy in resected stage IB-IIIA non-small-cell lung cancer (NSCLC) after…
- Trial name
- CONTINUE (NCT06426511)
- Testing
- Toripalimab+Chemotherapy, Toripalimab+Chemotherapy followed by consolidation toripalimab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)
RGL-305+ Lymphoma + Exploratory Clinical Study
This study is an open, prospective, dose-increasing exploratory clinical trial. To evaluate the safety, cytodynamics and initial efficacy of RGL-305 in patients with lymphoma.
- Trial name
- NCT07006012
- Testing
- RGL-305
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Fudan University
Relapsed Acute Lymphoblastic Leukemia, Relapsed Acute Myelogenous Leukemia
Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
This is a phase I trial of an investigational drug called GNKG168 in patients with relapsed and refractory acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) who are in morphologic remission but are positive…
- Trial name
- NCT01743807
- Testing
- GNKG168
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Interferon-A-2B, Relapse
Interferon-α Prevents Leukemia Relapse of AML Patients After Transplantation
Allogeneic stem cell transplantation (SCT) remains a powerful therapeutic modality for patients with acute myeloid leukemia (AML).The superior clinical outcomes of allogeneic human SCT versus chemotherapy alone as post-remission…
- Conditions
- Interferon-A-2B, Relapse, Prevention, Hematopietic Stem Cell Transplantation
- Trial name
- NCT03121079
- Testing
- Interferon-alpha
- Where
- China
- Sponsor
- Peking University People's Hospital
Muscle-Invasive Bladder Carcinoma
Clinical Performance Evaluation of the C2i-Test
The C2i-WGS-MRD Test (hereinafter referred to as C2i-Test), a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS) based whole-genome sequencing…
- Trial name
- NCT05221827
- Testing
- C2i Test
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- C2i Genomics
Stage IB-IIIB NSCLC, Stage IIB-III NSCLC
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy
This is a two-cohort, multicenter, Phase II study to evaluate the efficacy and safety of 3-4 cycles of toripalimab (JS001) plus chemotherapy followed by toripalimab maintenance treatment up to one year in participants with…
- Trial name
- NCT07039656
- Testing
- Toripalimab, Cisplatin-based chemotherapy
- Where
- China
- Volunteers
- 211 people
- Sponsor
- Wen-zhao ZHONG
Hairy Cell Leukemia
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Background: Researchers are attempting to develop new treatments for hairy cell leukemia (HCL) that has not responded well to or has recurred after standard HCL therapies.
- Trial name
- NCT01059786
- Testing
- Pentostatin, Rituximab, Bendamustine
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
The REMNANT study will evaluate whether treating minimal residual disease (MRD) relapse after first line treatment prolongs progression free survival and overall survival for myeloma patients versus treating relapse after first…
- Trial name
- NCT04513639
- Testing
- Early treatment of relapse with carfilzomib, dexamethasone, daratumumab, Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab
- Where
- 13 sites in Norway
- Volunteers
- 176 people
- Sponsor
- Oslo University Hospital
Light Chain (AL) Amyloidosis, MRD
A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
Before effective treatment, the prognosis of patients with AL amyloidosis is very poor, with a median survival of approximately 12 months.
- Trial name
- NCT07215494
- Testing
- First-Line Dara-BorCyD Treatment
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University First Hospital
Acute Myeloid Leukemia
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in…
- Trial name
- NCT04086264
- Testing
- Azacitidine, IMGN632, Venetoclax
- Where
- 29 sites in United States, France and 4 more
- Volunteers
- 218 people
- Sponsor
- AbbVie
Waldenstrom's Disease
Detection of Recurrent Mutations in Waldenström's Disease
Waldenström's disease (WM) is a rare, low-grade lymphoid hematopathy, accounting for 1 to 2% of malignant hematopathies and mainly affecting the elderly.
- Trial name
- DigiWAL (NCT03952052)
- Testing
- Determination of mutation
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Henri Becquerel
B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
This is a single-center, open-label, exploratory study evaluating ifupinostat hydrochloride (BEBT-908) in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with MEF2D rearrangement.
- Trial name
- NCT07854652
- Testing
- Ifupinostat Hydrochloride
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Colorectal Cancer, Minimal Residual Disease
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
To find the highest and/or recommended dose of TROP2-CAR-NK cells combined with cetuximab in participants with MRD CRC.
- Trial name
- NCT06358430
- Testing
- Fludarabine Phosphate, Cyclophosphamide, Cetuximab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer
The aim of this clinical trial is to test whether minimal residual disease (MRD) status detected by circulating tumor DNA (ctDNA) could be used to guide precision therapy of post-surgery in colon cancer.
- Trial name
- MIRROR (NCT06204484)
- Testing
- CAPEOX adjuvant therapy, deferred CAPEOX adjuvant therapy, mFOLFOXIRI intensive adjuvant therapy
- Where
- China
- Volunteers
- 349 people
- Sponsor
- Sun Yat-sen University
Acute Lymphoblastic Leukemia
Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia
The aim of this clinical study in adult ALL is to compare by risk category (1) the feasibility of two different CNS prophylaxis regimens and (2) the overall disease-free survival in relation to the achievement of an early MRD…
- Trial name
- NCT00795756
- Testing
- liposome-encapsulated cytarabine (DepoCyte), Triple intrathecal therapy (TIT)
- Where
- 16 sites in Italy
- Volunteers
- 145 people
- Sponsor
- Northern Italy Leukemia Group
B-cell Adult Acute Lymphoblastic Leukemia, Stem Cell Leukemia
Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant
This is a single arm, open label, multi-centre phase II study using blinatumomab for treatment of detectable minimal residual disease (MRD) in the first year following allogeneic hematopoietic stem cell transplant (HSCT) for…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, Stem Cell Leukemia, Minimal Residual Disease
- Trial name
- OZM-097 (NCT04044560)
- Testing
- blinatumomab
- Where
- 3 sites in Canada
- Volunteers
- 8 people
- Sponsor
- University of British Columbia
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
This phase II trial studies how well cytarabine and idarubicin or daunorubicin with or without pembrolizumab work in treating patients with newly-diagnosed acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
- Trial name
- NCT04214249
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)